Compare · CGON vs GILD
CGON vs GILD
Side-by-side comparison of CG Oncology Inc. (CGON) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGON and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.93B, about 29.7x CGON ($5.25B).
- Over the past year, CGON is up 134.1% and GILD is up 13.3% - CGON leads by 120.8 points.
- GILD has been more active in the news (15 items in the past 4 weeks vs 10 for CGON).
- GILD has more recent analyst coverage (25 ratings vs 16 for CGON).
- Company
- CG Oncology Inc.
- Gilead Sciences Inc.
- Price
- $59.59+3.41%
- $125.60-0.17%
- Market cap
- $5.25B
- $155.93B
- 1M return
- -19.51%
- -5.59%
- 1Y return
- +134.12%
- +13.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 10
- 15
- Recent ratings
- 16
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest CGON
- SEC Form 8-K filed by CG Oncology Inc.
- SEC Form 4 filed by Director Liu Brian Guan-Chyun
- SEC Form 4 filed by Director Tong Victor Edward Jr
- SEC Form 4 filed by Director Mulay James
- SEC Form 4 filed by Director Graf Susan E
- SEC Form 4 filed by Director Rossi Christina
- Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $54,500 worth of shares (1,000 units at $54.50) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by CG Oncology Inc.
- CG Oncology to Present at Upcoming Investor Conferences in June
- CG Oncology Inc. filed SEC Form 8-K: Leadership Update
Latest GILD
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE